<div id="readability-page-1"><p>RBC Capital analyst Luca Issi downgraded Korro Bio to a Hold yesterday and set a price target of $8.00. The company’s shares closed yesterday at $6.50.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Issi covers the Healthcare sector, focusing on stocks such as uniQure, Ascendis Pharma, and Alnylam Pharma. According to TipRanks, Issi has an average return of <span>6.7%</span> and a 41.16% success rate on recommended stocks. </p> <p>In addition to RBC Capital, Korro Bio also received a Hold from Cantor Fitzgerald’s Steven Seedhouse in a report issued yesterday. However, on October 30, Clear Street initiated coverage with a Buy rating on Korro Bio (NASDAQ: KRRO).</p></div>

KRRO

<p>RBC Capital analyst Luca Issi downgraded Korro Bio (KRRO) to a Hold with a price target of $8.00, while the stock closed at $6.50. Cantor Fitzgerald also rated it as Hold, but Clear Street initiated coverage with a Buy rating on October 30. Issi, who covers the Healthcare sector, has an average return of 6.7% and a 41.16% success rate on recommended stocks.</p>

RBC Capital downgrades Korro Bio (KRRO) to a Hold